Literature DB >> 16563392

Hepatic guanylate cyclase activity is decreased in a model of cirrhosis: a quantitative cytochemistry study.

Nathan A Davies1, Stephen J Hodges, Andrew A Pitsillides, Rajeshwar P Mookerjee, Rajiv Jalan, Siroos Mehdizadeh.   

Abstract

The production of nitric oxide (NO) in liver disease and its role in vascular control has been a subject of much interest in recent years. However, the activity of guanylate cyclase (GC), the enzyme activated by NO has received little attention with regard to liver disease. In this study we have utilised a quantitative cytochemical technique to examine the activity of GC on a per cell basis in a rat model of cirrhosis. Our results show a significant reduction in GC activity, indicating that vascular regulation is likely to be substantially affected irrespective of NO generation in this disease model.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563392     DOI: 10.1016/j.febslet.2006.02.080

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  8 in total

Review 1.  Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.

Authors:  Seong Hee Kang; Moon Young Kim; Soon Koo Baik
Journal:  Hepatol Int       Date:  2017-07-11       Impact factor: 6.047

2.  Nitric oxide and L-arginine metabolism in a devascularized porcine model of acute liver failure.

Authors:  Vikram Sharma; Gabriella A M Ten Have; Lars Ytrebo; Sambit Sen; Christopher F Rose; R Neil Dalton; Charles Turner; Arthur Revhaug; Hans M H van-Eijk; Nicolaas E P Deutz; Rajiv Jalan; Rajeshwar P Mookerjee; Nathan A Davies
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-15       Impact factor: 4.052

3.  Cardiac-induced liver deformation as a measure of liver stiffness using dynamic imaging without magnetization tagging-preclinical proof-of-concept, clinical translation, reproducibility and feasibility in patients with cirrhosis.

Authors:  Manil D Chouhan; Heather E Fitzke; Alan Bainbridge; David Atkinson; Steve Halligan; Nathan Davies; Mark F Lythgoe; Rajeshwar P Mookerjee; Alex Menys; Stuart A Taylor
Journal:  Abdom Radiol (NY)       Date:  2021-06-20

4.  Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver.

Authors:  Leonie Halverscheid; Peter Deibert; René Schmidt; Hubert E Blum; Torsten Dunkern; Benedikt H J Pannen; Wolfgang Kreisel
Journal:  BMC Gastroenterol       Date:  2009-09-18       Impact factor: 3.067

5.  Establishment of a reversible model of prehepatic portal hypertension in rats.

Authors:  Xin Zhao; Jian Dou; Qing-Jun Gao
Journal:  Exp Ther Med       Date:  2016-05-30       Impact factor: 2.447

6.  Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up.

Authors:  Peter Deibert; Adhara Lazaro; Zoran Stankovic; Denise Schaffner; Martin Rössle; Wolfgang Kreisel
Journal:  World J Gastroenterol       Date:  2018-01-21       Impact factor: 5.742

7.  Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension.

Authors:  Denise Schaffner; Adhara Lazaro; Peter Deibert; Peter Hasselblatt; Patrick Stoll; Lisa Fauth; Manfred W Baumstark; Irmgard Merfort; Annette Schmitt-Graeff; Wolfgang Kreisel
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

Review 8.  Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension.

Authors:  Wolfgang Kreisel; Denise Schaffner; Adhara Lazaro; Jonel Trebicka; Irmgard Merfort; Annette Schmitt-Graeff; Peter Deibert
Journal:  Int J Mol Sci       Date:  2020-08-28       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.